Comorbidities in Mild Autonomous Cortisol Secretion – A Clinical Review of Literature

Abstract

Mild autonomous cortisol secretion (mACS) is a state of cortisol excess usually associated with existence of adrenal incidentaloma. Because of the lack of symptoms of the disease, the biochemical evaluation is the most important to determine a diagnosis. However, scientific societies have different diagnostic criteria for mACS, which makes the treatment of this disease and using results of original papers in daily practice more difficult. Chronic hypercortisolemic state, even if mild, may lead to diseases that are mostly connected with overt Cushing’s syndrome. Some of them can cause a higher mortality of patients with mACS and those problems need to be addressed. In this review we describe the comorbidities associated with mACS: cardiovascular disorders, arterial hypertension, diabetes mellitus, insulin resistance, dyslipidemia, obesity, metabolic syndrome, non-alcoholic fatty liver disease, vertebral fractures and osteoporosis. The point of this paper is to characterise them and determine if and how these conditions should be managed. Two databases – PubMed and Web of Science were searched. Even though the evidence are scarce, this is an attempt to lead clinicians through the problems associated with this enigmatic condition.

Key words

mild autonomous cortisol secretion - subclinical hypercortisolism - adrenal incidentaloma - vertebral fractures - osteoporosis - arterial hypertension - diabetes mellitus - insulin resistance - obesity - metabolic syndrome

Publication History

Received: 26 September 2021
Received: 09 March 2022

Accepted: 01 April 2022

Article published online:
11 July 2022

• References

• 1 Lee SH, Song KH, Kim J. et al. New diagnostic criteria for subclinical hypercortisolism using postsurgical hypocortisolism: The co-work of Adrenal Research study. Clin Endocrinol 2017; 86: 10-18 DOI: 10.1111/cen.13145.
• 2 Fassnacht M, Arlt W, Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34
• 3 NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). 2002; 19
• 4 Zeiger MA, Thompson GB, Duh Q-Y. et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the management of adrenal incidentalomas. Endocr Pract 2009; 15: 1-20 DOI: 10.4158/EP.15.S1.1.
• 5 Terzolo M, Stigliano A, Chiodini I. et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164: 851-870 DOI: 10.1530/EJE-10-1147.
• 6 Ebbehoj A, Li D, Kaur RJ. et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: A population-based cohort study. Lancet Diabetes Endocrinol 2020; 8: 894-902 DOI: 10.1016/S2213-8587(20)30314-4.
• 7 Di Dalmazi G, Pasquali R. Adrenal adenomas, subclinical hypercortisolism, and cardiovascular outcomes. Curr Opin Endocrinol Diabetes Obes 2015; 22: 163-168 DOI: 10.1097/MED.0000000000000153.
• 8 Rossi R, Tauchmanova L, Luciano A. et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: Clinical and biochemical features. J Clin Endocrinol Metab 2000; 85: 1440-1448 DOI: 10.1210/jcem.85.4.6515.
• 9 Francucci CM, Pantanetti P, Garrapa GG. et al. Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma. Clin Endocrinol 2002; 57: 587-593 DOI: 10.1046/j.1365-2265.2002.01602.x.
• 10 Chiodini I, Mascia ML, Muscarella S. et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med 2007; 147: 541 DOI: 10.7326/0003-4819-147-8-200710160-00006.
• 11 Chiodini I, Torlontano M, Carnevale V. et al. Bone loss rate in adrenal incidentalomas: A longitudinal study. J Clin Endocrinol Metab 2001; 86: 5337-5341 DOI: 10.1210/jcem.86.11.8022.
• 12 Kalpakcioglu BB, Engelke K, Genant HK. Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone 2011; 48: 1221-1231 DOI: 10.1016/j.bone.2011.02.005.
• 13 dos Santos CV, Vieira Neto L, Madeira M. et al. Bone density and microarchitecture in endogenous hypercortisolism. Clin Endocrinol 2015; 83: 468-474 DOI: 10.1111/cen.12812.
• 14 Morelli V, Eller-Vainicher C, Salcuni AS. et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: A multicenter longitudinal study. J Bone Miner Res 2011; 26: 1816-1821 DOI: 10.1002/jbmr.398.
• 15 Chiodini I, Guglielmi G, Battista C. et al. Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: The effects of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 2004; 89: 2237-2241 DOI: 10.1210/jc.2003-031413.
• 16 Torlontano M, Chiodini I, Pileri M. et al. Altered bone mass and turnover in female patients with adrenal incidentaloma: The effect of subclinical hypercortisolism. J Clin Endocrinol Metab 1999; 84: 2381-2385 DOI: 10.1210/jcem.84.7.5856.
• 17 Tauchmanova L, Rossi R, Nuzzo V. et al. Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass. Eur J Endocrinol 2001; 145: 241-247 DOI: 10.1530/eje.0.1450241.
• 18 Chiodini I, Tauchmanovà L, Torlontano M. et al. Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism. J Clin Endocrinol Metab 2002; 87: 5491-5494 DOI: 10.1210/jc.2002-020399.
• 19 Chiodini I, Viti R, Coletti F. et al. Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. Clin Endocrinol 2009; 70: 208-213 DOI: 10.1111/j.1365-2265.2008.03310.x.
• 20 Chiodini I, Morelli V, Masserini B. et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: An Italian multicenter study. J Clin Endocrinol Metab 2009; 94: 3207-3214 DOI: 10.1210/jc.2009-0468.
• 21 Eller-Vainicher C, Morelli V, Ulivieri FM. et al. Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J Bone Miner Res 2012; 27: 2223-2230 DOI: 10.1002/jbmr.1648.
• 22 Lasco A, Catalano A, Pilato A. et al. Subclinical hypercortisol-assessment of bone fragility: Experience of single osteoporosis center in Sicily. Eur Rev Med Pharmacol Sci 2014; 18: 352-358
• 23 Ognjanović S, Macut D, Petakov M. et al. The occurrence of subclinical hypercortisolism and osteoporosis in patients with incidentally discovered unilateral and bilateral adrenal tumors. J Med Biochem 2016; 35: 401-409 DOI: 10.1515/jomb-2016-0020.
• 24 Vassilatou E, Vryonidou A, Ioannidis D. et al. Bilateral adrenal incidentalomas differ from unilateral adrenal incidentalomas in subclinical cortisol hypersecretion but not in potential clinical implications. Eur J Endocrinol 2014; 171: 37-45 DOI: 10.1530/EJE-13-0848.
• 25 Harvey NC, Glüer CC, Binkley N. et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 2015; 78: 216-224 DOI: 10.1016/j.bone.2015.05.016.
• 26 Vinolas H, Grouthier V, Mehsen-Cetre N. et al. Assessment of vertebral microarchitecture in overt and mild Cushing’s syndrome using trabecular bone score. Clin Endocrinol 2018; 89: 148-154 DOI: 10.1111/cen.13743.
• 27 Leib ES, Winzenrieth R. Bone status in glucocorticoid-treated men and women. Osteoporos Int 2016; 27: 39-48 DOI: 10.1007/s00198-015-3211-1.
• 28 Silva BC, Walker MD, Abraham A. et al. Trabecular bone score is associated with volumetric bone density and microarchitecture as assessed by central QCT and HRpQCT in Chinese American and White Women. J Clin Densitom 2013; 16: 554-561 DOI: 10.1016/j.jocd.2013.07.001.
• 29 McCloskey EV, Odén A, Harvey NC. et al. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 2016; 31: 940-948 DOI: 10.1002/jbmr.2734.
• 30 Crans GG, Genant HK, Krege JH. Prognostic utility of a semiquantitative spinal deformity index. Bone 2005; 37: 175-179 DOI: 10.1016/j.bone.2005.04.003.
• 31 Genant HK, Delmas PD, Chen P. et al. Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 2007; 18: 69-76 DOI: 10.1007/s00198-006-0199-6.
• 32 Morelli V, Eller-Vainicher C, Palmieri S. et al. Prediction of vertebral fractures in patients with monolateral adrenal incidentalomas. J Clin Endocrinol Metab 2016; 101: 2768-2775 DOI: 10.1210/jc.2016-1423.
• 33 Morelli V, Reimondo G, Giordano R. et al. Long-term follow-up in adrenal incidentalomas: An Italian multicenter study. J Clin Endocrinol Metab 2014; 99: 827-834 DOI: 10.1210/jc.2013-3527.
• 34 Di Dalmazi G, Vicennati V, Garelli S. et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: A 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2: 396-405 DOI: 10.1016/S2213-8587(13)70211-0.
• 35 Debono M, Bradburn M, Bull M. et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014; 99: 4462-4470 DOI: 10.1210/jc.2014-3007.
• 36 Tabarin A, Bardet S, Bertherat J. et al. Exploration and management of adrenal incidentalomas. Ann Endocrinol (Paris) 2008; 69: 487-500 DOI: 10.1016/j.ando.2008.09.003.
• 37 Chiodini I, Francucci CM, Scillitani A. Densitometry in glucocorticoid-induced osteoporosis. J Endocrinol Investig 2008; 31: 33-37
• 38 Ahn SH, Kim JH, Cho YY. et al. The effects of cortisol and adrenal androgen on bone mass in Asians with and without subclinical hypercortisolism. Osteoporos Int 2019; 30: 1059-1069 DOI: 10.1007/s00198-019-04871-5.
• 39 Tauchmanova L, Pivonello R, de Martino MC. et al. Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. Eur J Endocrinol 2007; 157: 359-366 DOI: 10.1530/EJE-07-0137.
• 40 Morelli V, Masserini B, Salcuni AS. et al. Subclinical hypercortisolism: Correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol 2010; 73: 161-166 DOI: 10.1111/j.1365-2265.2010.03794.x.
• 41 Siggelkow H, Etmanski M, Bozkurt S. et al. Genetic polymorphisms in 11β-hydroxysteroid dehydrogenase type 1 correlate with the postdexamethasone cortisol levels and bone mineral density in patients evaluated for osteoporosis. J Clin Endocrinol Metab 2014; 99: E293-E302 DOI: 10.1210/jc.2013-1418.
• 42 Szappanos Á, Patócs A, Gergics P. et al. The 83,557insA variant of the gene coding 11β-hydroxysteroid dehydrogenase type 1 enzyme associates with serum osteocalcin in patients with endogenous Cushing’s syndrome. J Steroid Biochem Mol Biol 2011; 123: 79-84 DOI: 10.1016/j.jsbmb.2010.11.009.
• 43 Kim B-J, Kwak MK, Ahn SH. et al. The association of cortisol and adrenal androgen with trabecular bone score in patients with adrenal incidentaloma with and without autonomous cortisol secretion. Osteoporos Int 2018; 29: 2299-2307 DOI: 10.1007/s00198-018-4608-4.
• 44 Di Dalmazi G, Vicennati V, Rinaldi E. et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: A large cross-sectional study. Eur J Endocrinol 2012; 166: 669-677 DOI: 10.1530/EJE-11-1039.
• 45 Vassilatou E, Vryonidou A, Michalopoulou S. et al. Hormonal activity of adrenal incidentalomas: Results from a long-term follow-up study. Clin Endocrinol 2009; 70: 674-679 DOI: 10.1111/j.1365-2265.2008.03492.x.
• 46 Androulakis II, Kaltsas GA, Kollias GE. et al. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab 2014; 99: 2754-2762 DOI: 10.1210/jc.2013-4064.
• 47 Sereg M, Szappanos Á, Tőke J. et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: A long-term follow-up study. Eur J Endocrinol 2009; 160: 647-655 DOI: 10.1530/EJE-08-0707.
• 48 Petramala L, Olmati F, Concistrè A. et al. Cardiovascular and metabolic risk factors in patients with subclinical Cushing. Endocrine 2020; 70: 150-163 DOI: 10.1007/S12020-020-02297-2.
• 49 Morelli V, Palmieri S, Lania A. et al. Cardiovascular events in patients with mild autonomous cortisol secretion: Analysis with artificial neural networks. Eur J Endocrinol 2017; 177: 73-83 DOI: 10.1530/EJE-17-0047.
• 50 Patrova J, Kjellman M, Wahrenberg H. et al. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: A 13-year retrospective study from one center. Endocrine 2017; 58: 267-275 DOI: 10.1007/s12020-017-1400-8.
• 51 Prete A, Subramanian A, Bancos I. et al. Cardiometabolic disease burden and steroid excretion in benign adrenal tumors: A cross-sectional multicenter study. Ann Intern Med 2022; 175: 325-334 DOI: 10.7326/M21-1737.
• 52 Zhang CD, Li D, Kaur RJ. et al. Cardiometabolic outcomes and mortality in patients with adrenal adenomas in a population-based setting. J Clin Endocrinol Metab 2021; 106: 3320-3330 DOI: 10.1210/CLINEM/DGAB468.
• 53 Ortiz R, Joseph JJ, Lee R. et al. Type 2 diabetes and cardiometabolic risk may be associated with increase in DNA methylation of FKBP5. Clin Epigenetics 2018; 10 DOI: 10.1186/s13148-018-0513-0.
• 54 Imga NN, Topcuoglu C, Berker D. et al. Serum amyloid A, paraoxonase-1 activity, and apolipoprotein concentrations as biomarkers of subclinical atherosclerosis risk in adrenal incidentaloma patients. Arch Med Res 2018; 49: 182-190 DOI: 10.1016/j.arcmed.2018.07.002.
• 55 Shufelt C, Bretsky P, Almeida CM. et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010; 95: 4985-4992 DOI: 10.1210/jc.2010-0143.
• 56 Pereg D, Gow R, Mosseri M. et al. Hair cortisol and the risk for acute myocardial infarction in adult men. Stress 2011; 14: 73-81 DOI: 10.3109/10253890.2010.511352.
• 57 Pereg D, Chan J, Russell E. et al. Cortisol and testosterone in hair as biological markers of systolic heart failure. Psychoneuroendocrinology 2013; 38: 2875-2882 DOI: 10.1016/j.psyneuen.2013.07.015.
• 58 Erbil Y, Ozbey N, Barbaros U. et al. Cardiovascular risk in patients with nonfunctional adrenal incidentaloma: Myth or reality?. World J Surg 2009; 33: 2099-2105 DOI: 10.1007/s00268-009-0178-0.
• 59 Tauchmanovà L, Rossi R, Biondi B. et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87: 4872-4878 DOI: 10.1210/jc.2001-011766.
• 60 Neary NM, Booker OJ, Abel BS. et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: Analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab 2013; 98: 2045-2052 DOI: 10.1210/jc.2012-3754.
• 61 Iacobellis G, Petramala L, Barbaro G. et al. Epicardial fat thickness and left ventricular mass in subjects with adrenal incidentaloma. Endocrine 2013; 44: 532-536 DOI: 10.1007/S12020-013-9902-5.
• 62 Sbardella E, Minnetti M, D’Aluisio D. et al. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. Eur J Endocrinol 2018; 178: 501-511 DOI: 10.1530/EJE-17-0986.
• 63 Kamenický P, Redheuil A, Roux C. et al. Cardiac structure and function in Cushing’s syndrome: A cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 2014; 99: E2144-E2153 DOI: 10.1210/JC.2014-1783.
• 64 di Dalmazi G, Vicennati V, Pizzi C. et al. Prevalence and incidence of atrial fibrillation in a large cohort of adrenal incidentalomas: A long-term study. J Clin Endocrinol metab 2020; 105 DOI: 10.1210/CLINEM/DGAA270.
• 65 Costa DS, Conceição FL, Leite NC. et al. Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study. J Diabetes Complicat 2016; 30: 1032-1038 DOI: 10.1016/j.jdiacomp.2016.05.006.
• 66 Kumari M, Shipley M, Stafford M. et al. Association of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: Findings from the Whitehall II Study. J Clin Endocrinol Metab 2011; 96: 1478-1485 DOI: 10.1210/jc.2010-2137.
• 67 Vogelzangs N, Beekman ATF, Milaneschi Y. et al. Urinary cortisol and six-year risk of all-cause and cardiovascular mortality. J Clin Endocrinol Metab 2010; 95: 4959-4964 DOI: 10.1210/jc.2010-0192.
• 68 Ronaldson A, Kidd T, Poole L. et al. Diurnal cortisol rhythm is associated with adverse cardiac events and mortality in coronary artery bypass patients. J Clin Endocrinol Metab 2015; 100: 3676-3682 DOI: 10.1210/jc.2015-2617.
• 69 Mullan K, Black N, Thiraviaraj A. et al. Is there value in routine screening for Cushing’s syndrome in patients with diabetes?. J Clin Endocrinol Metab 2010; 95: 2262-2265 DOI: 10.1210/jc.2009-2453.
• 70 Chiodini I, Torlontano M, Scillitani A. et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: A case-control study in hospitalized patients. Eur J Endocrinol 2005; 153: 837-844 DOI: 10.1530/eje.1.02045.
• 71 Leibowitz G, Tsur A, Chayen SD. et al. Pre-clinical Cushing’s syndrome: An unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol 1996; 44: 717-722 DOI: 10.1046/j.1365-2265.1996.737558.x.
• 72 Reimondo G, Pia A, Allasino B. et al. Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol 2007; 67: 225-229 DOI: 10.1111/j.1365-2265.2007.02865.x.
• 73 Terzolo M, Reimondo G, Chiodini I. et al. Screening of Cushing’s syndrome in outpatients with type 2 diabetes: Results of a prospective multicentric study in Italy. J Clin Endocrinol Metab 2012; 97: 3467-3475 DOI: 10.1210/jc.2012-1323.
• 74 Taniguchi T, Hamasaki A, Okamoto M. Subclinical hypercortisolism in hospitalized patients with type 2 diabetes mellitus. Endocrine J 2008; 55: 429-432 DOI: 10.1507/endocrj.k07e-045.
• 75 Murakami H, Nigawara T, Sakihara S. et al. The frequency of type 2 diabetic patients who meet the endocrinological screening criteria of subclinical Cushing’s disease. Endocrine J 2010; 57: 267-272 DOI: 10.1507/endocrj.k09e-352.
• 76 Terzolo M, Bovio S, Reimondo G. et al. Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 2005; 34: 423-439 DOI: 10.1016/j.ecl.2005.01.008.
• 77 Terzolo M, Pia A, Alì A. et al. Adrenal incidentaloma: A new cause of the metabolic syndrome?. J Clin Endocrinol Metab 2002; 87: 998-1003 DOI: 10.1210/jcem.87.3.8277.
• 78 Terzolo M, Bovio S, Pia A. et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol 2005; 153: 307-315 DOI: 10.1530/eje.1.01959.
• 79 Giordano R, Marinazzo E, Berardelli R. et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol 2010; 162: 779-785 DOI: 10.1530/EJE-09-0957.
• 80 Vukomanovic VR, Ignjatovic VD, Mihaljevic O. et al. Glucose and lipid abnormalities in patients with adrenal incidentalomas. Hell J Nucl Med 2019; 22: 7-14
• 81 Reincke M, Faßnacht M, Väth S. et al. Adrenal incidentalomas: A manifestation of the metabolic syndrome?. Endocr Res 1996; 22: 757-761 DOI: 10.1080/07435809609043773.
• 82 Evran M, Akkuş G, Berk Bozdoğan İ. et al. Carotid intima-media thickness as the cardiometabolic risk indicator in patients with nonfunctional adrenal mass and metabolic syndrome screening. Med Sci Monit 2016; 22: 991-997 DOI: 10.12659/MSM.897714.
• 83 Ivović M, Marina LV, Vujović S. et al. Nondiabetic patients with either subclinical Cushing’s or nonfunctional adrenal incidentalomas have lower insulin sensitivity than healthy controls: Clinical implications. Metabolism 2013; 62: 786-792 DOI: 10.1016/j.metabol.2012.12.006.
• 84 Cansu GB, Atılgan S, Balcı MK. et al. Which type 2 diabetes mellitus patients should be screened for subclinical Cushing’s syndrome?. Hormones 2017; 16: 22-32 DOI: 10.14310/horm.2002.1716.
• 85 Budyal S, Jadhav SS, Kasaliwal R. et al. Is it worthwhile to screen patients with type 2 diabetes mellitus for subclinical Cushing’s syndrome?. Endocr Connect 2015; 4: 242-248 DOI: 10.1530/ec-15-0078.
• 86 Krarup T, Krarup T, Hagen C. Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing’s syndrome?. Diabetes/Metab Res Rev 2012; 28: 219-227 DOI: 10.1002/dmrr.2262.
• 87 Asao T, Oki K, Yoneda M. et al. Hypothalamic-pituitary-adrenal axis activity is associated with the prevalence of chronic kidney disease in diabetic patients. Endocrine J 2016; 63: 119-126 DOI: 10.1507/endocrj.EJ15-0360.
• 88 Notarianni E. Cortisol: Mediator of association between Alzheimer’s disease and diabetes mellitus?. Psychoneuroendocrinology 2017; 81: 129-137
• 89 Peppa M, Boutati E, Koliaki C. et al. Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: A cause-effect relationship?. Metabolism 2010; 59: 1435-1441 DOI: 10.1016/j.metabol.2010.01.007.
• 90 Peppa M, Koliaki C, Raptis SA. Adrenal incidentalomas and cardiometabolic morbidity: An emerging association with serious clinical implications. J Intern Med 2010; 268: 555-566 DOI: 10.1111/j.1365-2796.2010.02291.x.
• 91 Masserini B, Morelli V, Palmieri S. et al. Lipid abnormalities in patients with adrenal incidentalomas: role of subclinical hypercortisolism and impaired glucose metabolism. J Endocrinol Investig 2015; 38: 623-628 DOI: 10.1007/s40618-014-0232-0.
• 92 Kim JH, Kwak MK, Ahn SH. et al. Alteration in skeletal muscle mass in women with subclinical hypercortisolism. Endocrine 2018; 61: 134-143 DOI: 10.1007/S12020-018-1598-0.
• 93 Delivanis DA, Iñiguez-Ariza NM, Zeb MH. et al. Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in patients with adrenal adenomas. Clin Endocrinol 2018; 88: 209-216 DOI: 10.1111/CEN.13512.
• 94 Naka M, Kadoya M, Kosaka-Hamamoto K. et al. Overestimation of glomerular filtration rate calculated from serum creatinine as compared with cystatin C in patients with subclinical hypercortisolism: Hyogo Adrenal Metabolic Registry. Endocrine J 2020; 67: 469-476 DOI: 10.1507/ENDOCRJ.EJ19-0478.
• 95 Zoppini G, Targher G, Venturi C. et al. Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. Clin Endocrinol 2004; 61: 711-715 DOI: 10.1111/j.1365-2265.2004.02154.x.
• 96 Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235-240 DOI: 10.1016/j.atherosclerosis.2006.08.021.
• 97 Targher G, Bertolini L, Zoppini G. et al. Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients. Diabetic Medicine 2005; 22: 1146-1150 DOI: 10.1111/j.1464-5491.2005.01583.x.
• 98 Westerbacka J, Yki-Järvinen H, Vehkavaara S. et al. Body fat distribution and cortisol metabolism in healthy men: Enhanced 5β-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 2003; 88: 4924-4931 DOI: 10.1210/jc.2003-030596.
• 99 Hubel J, Schmidt S, Mason R. et al. Influence of plasma cortisol and other laboratory parameters on nonalcoholic fatty liver disease. Hormone Metab Res 2015; 47: 479-484 DOI: 10.1055/s-0034-1389982.
• 100 Papanastasiou L, Pappa T, Samara C. et al. Nonalcoholic fatty liver disease in subjects with adrenal incidentaloma. Eur J Clin Investig 2012; 42: 1165-1172 DOI: 10.1111/j.1365-2362.2012.02707.x.
• 101 Salcuni AS, Morelli V, Eller Vainicher C. et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. Eur J Endocrinol 2016; 174: 261-269 DOI: 10.1530/EJE-15-0977.
• 102 Randazzo ME, Grossrubatscher E, Dalino Ciaramella P. et al. Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 2012; 15: 193-201 DOI: 10.1007/s11102-011-0306-3.
• 103 Toniato A, Merante-Boschin I, Opocher G. et al. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: A prospective randomized study. Ann Surg 2009; 249: 388-391 DOI: 10.1097/SLA.0b013e31819a47d2.
• 104 Tauchmanova L, Guerra E, Pivonello R. et al. Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing’s syndrome. J Endocrinol Investig 2009; 32: 390-394 DOI: 10.1007/BF03346473.
• 105 Numakura K, Nara T, Kanda S. et al. Overweight patients less improved kidney function after laparoscopic surgery for adrenocortical adenoma with excess cortisol secretion. Front Endocrinol 2019; 10 DOI: 10.3389/fendo.2019.00572.
• 106 Chiodini I, Morelli V, Salcuni AS. et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010; 95: 2736-2745 DOI: 10.1210/jc.2009-2387.
• 107 Iacobone M, Citton M, Viel G. et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing’s syndrome. Surgery 2012; 152: 991-997 DOI: 10.1016/j.surg.2012.08.054.
• 108 Tsuiki M, Tanabe A, Takagi S. et al. Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing’s syndrome. Endocrine J 2008; 55: 737-745 DOI: 10.1507/endocrj.k07e-177.
• 109 Bernini G, Moretti A, Iacconi P. et al. Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol 2003; 148: 213-219 DOI: 10.1530/eje.0.1480213.
• 110 Papierska L, Ćwikła J, Rabijewski M. et al. Bilateral adrenal incidentaloma with subclinical hypercortisolemia: Indications for surgery. Pol Arch Med Wewn 2014; 124: 387-394 DOI: 10.20452/pamw.2347.
• 111 Bancos I, Alahdab F, Crowley RK. et al. THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing’s syndrome: A systematic review and meta-analysis. Eur J Endocrinol 2016; 175: R283-R295 DOI: 10.1530/EJE-16-0465.
• 112 Erbil Y, Ademoğlu E, Özbey N. et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006; 30: 1665-1671 DOI: 10.1007/s00268-005-0681-x.
• 113 Perogamvros I, Vassiliadi DA, Karapanou O. et al. Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas. Eur J Endocrinol 2015; 173: 719-725 DOI: 10.1530/EJE-15-0566.
• 114 Raffaelli M, de Crea C, D’Amato G. et al. Outcome of adrenalectomy for subclinical hypercortisolism and Cushing syndrome. Surgery 2016; 161: 264-271 DOI: 10.1016/j.surg.2016.07.042.